allurion.comCrawled Nov 10, 2026
The Allurion gastric balloon is the first and only non-surgical weight-loss device.
The Allurion gastric balloon capsule removes stubborn fat quickly and safely using a medical technique.
The Allurion gastric balloon pill helps users lose an average of 10 to 15 kg in 16 weeks.
The page displays gastric balloon results before and after, using patient reviews from Allurion.
The page shares patient reviews and success stories about Allurion’s gastric balloon results.
The page provides reviews and stories about Allurion’s gastric balloon.
The page shows before-and-after results of Allurion’s gastric balloon.
The page covers Allurion’s media coverage and multimedia content.
Allurion invites applicants from all backgrounds to join its gastric balloon industry team.
Allurion invites candidates from all backgrounds to start a career in the gastric balloon industry.
The page describes Allurion’s weight-loss program as fast, healthy, and affordable.
The Allurion promotional offer "Together Better" pairs users with a friend for weight-loss support and provides 1,000 dirhams to each.
Allurion’s medical weight-loss program helps people achieve their full potential.
The Allurion weight-loss program team helps people realize their full weight-loss potential.
The Allurion weight-loss program helps people achieve their full potential.
The Allurion medical weight-loss program helps people achieve their full potential.
The Allurion Gastric Balloon offers an alternative weight-loss solution. The page introduces Allurion and its company history.
The Allurion Gastric Balloon is a new, innovative alternative for weight loss. The page introduces Allurion and its company history.
Allurion provides a revolutionary treatment for weight issues, empowering users to live fuller lives.
The page explains what the Allurion Gastric Balloon is and directs users to an FAQ section.
The page describes the Allurion gastric balloon’s purpose and side effects in its FAQ section.
The page explains how the Allurion gastric balloon works and differentiates it from conventional options.
Allurion Technologies was founded in 2009. Its gastric balloon weight-loss program has helped thousands of people.
The Allurion weight-loss balloon and program were established in 2009, assisting thousands worldwide.
The Allurion Programme combines medical, digital, and nutritional approaches to support weight loss.
Allurion Technologies releases its second-quarter 2025 financial results, highlighting its focus on metabolically healthy weight loss solutions. The company provides an update on its business performance and operational progress in the weight management sector. Financial details and strategic developments are outlined for investors and stakeholders.
Allurion receives NYSE approval for its plan to regain compliance with listing requirements. The company submits a structured proposal to address outstanding conditions and restore its public trading status. The move follows prior delisting risks due to non-compliance with exchange standards.
Allurion introduces its first AI-driven compounded GLP-1 treatment program in the United States. The initiative leverages artificial intelligence to personalize obesity and metabolic health management. The program aims to expand access to compounded GLP-1 therapies while integrating advanced data analytics for patient monitoring.
Allurion submits the first three modules of its Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for its **Allurion Balloon** medical device. The submission marks a key regulatory milestone in the company’s efforts to bring the product to market. The Allurion Balloon is designed for gastrointestinal applications, targeting obesity and metabolic conditions.
Allurion adds pharmaceutical executive Keith Johns to its board. Johns brings over two decades of experience from Eli Lilly, where he held leadership roles in global operations and supply chain management. The appointment strengthens Allurion’s strategic oversight in drug delivery technologies.
Allurion names Ojas A. Buch as Chief Operating Officer. Buch joins to oversee operational strategy and execution for the agricultural technology company, which develops soil-monitoring solutions for farmers. The appointment follows Allurion’s expansion into new markets and product lines.
Allurion begins trading as a publicly listed company on the New York Stock Exchange (NYSE). The move follows the company’s transition to a public entity, marking its entry into the stock market.